Erturk, K., Tas, F., Serilmez, M., Bilgin, E., Yasasever, V. (2017). Clinical Signifıcance of Serum Ykl-40 (Chitinase-3-Like-1Protein) as a Biomarker in Melanoma: an Analysis of 112 Turkish Patients. Asian Pacific Journal of Cancer Prevention, 18(5), 1383-1387. doi: 10.22034/APJCP.2017.18.5.1383
Kayhan Erturk; Faruk Tas; Murat Serilmez; Elif Bilgin; Vildan Yasasever. "Clinical Signifıcance of Serum Ykl-40 (Chitinase-3-Like-1Protein) as a Biomarker in Melanoma: an Analysis of 112 Turkish Patients". Asian Pacific Journal of Cancer Prevention, 18, 5, 2017, 1383-1387. doi: 10.22034/APJCP.2017.18.5.1383
Erturk, K., Tas, F., Serilmez, M., Bilgin, E., Yasasever, V. (2017). 'Clinical Signifıcance of Serum Ykl-40 (Chitinase-3-Like-1Protein) as a Biomarker in Melanoma: an Analysis of 112 Turkish Patients', Asian Pacific Journal of Cancer Prevention, 18(5), pp. 1383-1387. doi: 10.22034/APJCP.2017.18.5.1383
Erturk, K., Tas, F., Serilmez, M., Bilgin, E., Yasasever, V. Clinical Signifıcance of Serum Ykl-40 (Chitinase-3-Like-1Protein) as a Biomarker in Melanoma: an Analysis of 112 Turkish Patients. Asian Pacific Journal of Cancer Prevention, 2017; 18(5): 1383-1387. doi: 10.22034/APJCP.2017.18.5.1383
Clinical Signifıcance of Serum Ykl-40 (Chitinase-3-Like-1Protein) as a Biomarker in Melanoma: an Analysis of 112 Turkish Patients
1Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey.
2Basic Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey.
Receive Date: 20 March 2017,
Revise Date: 25 April 2017,
Accept Date: 29 May 2017
Abstract
Background: Angiogenesis plays an essential role in tumor growth and serum levels of YKL-40 , a strong angiogenic factor that promotes tumor vessel development, has been found to be elevated in various cancers. We here investigated correlation between melanoma parameters and serum YKL-40 levels, to assess potential diagnostic, prognostic and predictive values. Material and Methods: Data for 112 pathologically confirmed cutaneous melanomas of any stage were examined retrospectively. ELISA assays were used to measure serum YKL-40 in plasma samples. Results: The baseline serum YKL-40 levels were significantly higher in patients than healthy controls (174.88 vs 120.10 ng/mL, p<0.001). However, values did not correlate with clinicopathological parameters, (p>0.05), and furthermore there was no apparent prognostic influence on melanoma survival (HR: 1.568; 95% CI, 0.580-3.051; p=0.838). Conclusion: Serum YKL-40 can be useful for diagnosis of melanoma, but reliability in assessing prognosis is questionable. We believe that efforts should be made to understand the interaction between YKL-40 and the tumor environment, and establish whether it might be the target for treatment of malignancies.
Top